The Plastic Chemical in 90% of Us: How BPA Quietly Rewires Human Hormones

Bisphenol A, the industrial chemical that hardens polycarbonate plastics and seals the epoxy linings of canned foods, has become one of the most intimately shared substances of modern life. Biomonitoring surveys consistently find its telltale metabolites in more than ninety percent of urine samples tested across diverse populations, a statistic that has transformed BPA from an obscure industrial intermediate into a central figure in environmental health research. A comprehensive review published in Discover Toxicology by Ram S. Kaulgud and colleagues at Karnataka Medical College and Research Institute synthesizes decades of evidence on how this ubiquitous compound interferes with the human endocrine system, and the picture it paints is both mechanistically intricate and deeply unsettling for anyone who has ever drunk from a plastic bottle.

The core of the problem lies in molecular mimicry. BPA’s structure bears a striking resemblance to steroidal estrogens such as diethylstilbestrol, allowing it to bind to estrogen receptors and exert estrogen-like effects in tissues ranging from the uterus and mammary glands to the brain and cardiovascular system. The review emphasizes that BPA binds to the estrogen receptor with an affinity roughly one thousand-fold lower than estradiol itself, which sounds reassuring until one considers the concentrations achieved in blood after a meal consumed from BPA-lined packaging. Crucially, the compound does not limit itself to estrogen receptors. It also interacts with androgen receptors, thyroid hormone receptors, glucocorticoid receptors, and the aryl hydrocarbon receptor, meaning that a single molecule can perturb multiple hormonal axes simultaneously, disrupting the synthesis, secretion, transport, metabolism, binding, and elimination of the body’s own hormones.

Perhaps the most technically significant advance highlighted in the review is the recognition that BPA’s actions extend far beyond the classical genomic pathway, in which a ligand enters the nucleus and alters gene transcription over hours. Recent mechanistic work shows that BPA also engages the G protein-coupled estrogen receptor, known as GPER, located on the cell membrane. Activation of GPER triggers rapid, non-genomic signaling cascades, including the cAMP/PKA pathway, PLC-mediated PKC activation, and transactivation of the epidermal growth factor receptor with downstream MAPK/ERK signaling. These membrane-initiated events have been implicated in altered immune signaling, with reduced interleukin-10 and interleukin-13 secretion observed in human immune cells, as well as in the promotion of cancer cell migration and invasiveness. Researchers argue that this rapid signaling mode helps explain the sometimes non-monotonic responses to BPA, in which low doses produce effects that higher doses do not, and they recommend that GPER engagement be explicitly considered when evaluating the safety of BPA substitutes.

That non-monotonic dose-response relationship strikes at the heart of conventional toxicology. Traditional risk assessment assumes that harm increases with dose, yet studies compiled in the review show measurable biological changes at doses within the range of everyday human exposure, levels often below those used in classic high-dose studies. In mice, in utero exposure to BPA reduced spine densities in the hippocampal CA1 region regardless of the dose administered to the mother, and the disruption of neuronal morphology persisted into adulthood. Such findings suggest that the developing brain, where hormones orchestrate neuronal differentiation, synapse formation, and overall cortical organization, is exquisitely vulnerable during critical windows of development. Exposure during these periods can produce long-lasting neurodevelopmental and behavioral deficits, including altered social behavior, anxiety, and changes in maternal behavior, effects documented across rodent models and zebrafish larvae, where BPA treatment decreased spontaneous movement and dysregulated genes associated with neurological system processes.

The epigenetic dimension adds an even more provocative layer. BPA exposure has been shown to alter DNA methylation patterns, the chemical tags that regulate gene expression without changing the underlying genetic code. Because epigenetic marks can be inherited through cell division and, in some cases, across generations, these modifications raise the possibility that today’s exposure could influence the health of descendants not yet born. Early-life exposure to endocrine disruptors has been associated with epigenetic reprogramming that manifests as increased disease risk later in life, a mechanism that may link prenatal BPA exposure to altered sexual differentiation, reduced fertility, and heightened susceptibility to reproductive cancers observed in animal models.

Sex differences emerge as a recurring theme throughout the evidence. Male, but not female, juvenile rats showed a noticeable decline in spatial memory following exposure to 0.4 milligrams per kilogram per day of BPA, while female offspring of mothers exposed to low doses were significantly heavier than controls or offspring exposed to high doses. Thyroid function tells a similarly paradoxical story: pooled analyses and recent cohort reports indicate that higher BPA concentrations are associated with lower free thyroxine and lower thyroid-stimulating hormone in males, whereas in females BPA is more often associated with higher free thyroxine, with TSH associations less consistent. The review attributes these divergent patterns to BPA’s multi-modal actions, including anti-androgenic effects and interference with thyroid hormone biosynthesis in males, and estrogenic modulation of thyroid hormone-binding proteins and peripheral deiodination in females.

Reproductive health bears the brunt of BPA’s interference in both sexes. In females, exposure disrupts the hypothalamic-pituitary-ovarian axis, interfering with gonadotropin-releasing hormone, luteinizing hormone, and follicle-stimulating hormone, pathways essential for ovulation and menstrual cycle regulation. BPA can also stimulate aromatase, the enzyme that converts androgens into estrogens, elevating estrogen levels and potentially promoting estrogen-dependent conditions such as endometriosis, uterine fibroids, and breast cancer, while simultaneously blocking progesterone signaling, a disruption linked to increased risks of miscarriage and preterm labor. In males, BPA disrupts the hypothalamic-pituitary-testicular axis, reduces the number and viability of testosterone-producing Leydig cells, and interferes with androgen receptor signaling, outcomes associated with reduced sperm production, impaired sperm motility, and altered luteinizing hormone levels that may reflect compensatory responses to falling testosterone.

The metabolic consequences may be equally consequential. Epidemiological studies suggest an association between high urinary BPA levels and predisposition to obesity, and animal experiments show that BPA promotes adipogenesis, increases fat accumulation, and disrupts glucose metabolism. Mechanistically, receptor-level endocrine disruption activates adipogenic transcriptional programs driven by PPARγ and C/EBPα, increases lipid accumulation and inflammatory signaling in adipose tissue, and impairs insulin signaling, providing a plausible pathway from plasticizer to metabolic syndrome. BPA can reduce cellular sensitivity to insulin by interfering with insulin receptor signaling, and may lower adiponectin, the hormone that helps regulate glucose and lipid metabolism. Recent work in mice even implicates gut microbiota-dependent bile acid metabolism and TGR5/UCP1 signaling in BPA-driven fat gain, with epigenetic reprogramming acting as an amplifying mediator.

Against this backdrop, the regulatory landscape remains fragmented and, in the view of the review’s authors, insufficient. The European Union, Canada, and China have banned BPA in baby bottles, the United States has restricted it in baby bottles and sippy cups, and California has imposed labeling requirements, yet the FDA has not banned BPA from all food and beverage containers and continues to monitor the evidence. Meanwhile, more than one hundred tons of BPA are discharged into the environment annually, leaching from containers into food, escaping from landfills and sewage treatment plants, and contaminating air, water, soil, and sediment. The industry’s pivot to substitutes, chiefly bisphenol S and bisphenol F, now common in thermal paper receipts, has not resolved safety concerns, as studies indicate these analogues may exert endocrine-disrupting effects similar to BPA’s. The review concludes that comprehensive toxicological evaluation of alternatives, transparent evidence-based policy, public education, improved labeling, and innovation in genuinely safer materials are urgently needed, because the evidence now shows that harm can occur at exposure levels people encounter every single day.

Subject of Research: Endocrine-disrupting effects of bisphenol A on human hormone systems and health outcomes

Article Title: Effects of Bisphenol-A on human endocrine function and health outcomes: a review

Article References: Effects of Bisphenol-A on human endocrine function and health outcomes: a review. (n.d.). https://doi.org/10.1007/s44339-025-00046-6

Image Credits: AI Generated

DOI: 10.1007/s44339-025-00046-6

Keywords: bisphenol A, endocrine disruptors, estrogen receptors, GPER, thyroid hormones, obesity, insulin resistance, reproductive health, epigenetics, brain development, BPS, BPF